JP2009502208A - エネルギーホメオスタシスに関係する新規ペプチド - Google Patents

エネルギーホメオスタシスに関係する新規ペプチド Download PDF

Info

Publication number
JP2009502208A
JP2009502208A JP2008525274A JP2008525274A JP2009502208A JP 2009502208 A JP2009502208 A JP 2009502208A JP 2008525274 A JP2008525274 A JP 2008525274A JP 2008525274 A JP2008525274 A JP 2008525274A JP 2009502208 A JP2009502208 A JP 2009502208A
Authority
JP
Japan
Prior art keywords
swirl
peptide
seq
mice
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008525274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502208A5 (enExample
Inventor
バトラー，アンドリュー・エイ
トレヴァスキス，ジェイムズ・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of JP2009502208A publication Critical patent/JP2009502208A/ja
Publication of JP2009502208A5 publication Critical patent/JP2009502208A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2008525274A 2005-08-05 2006-08-07 エネルギーホメオスタシスに関係する新規ペプチド Pending JP2009502208A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70594005P 2005-08-05 2005-08-05
PCT/US2006/030686 WO2007019426A2 (en) 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis

Publications (2)

Publication Number Publication Date
JP2009502208A true JP2009502208A (ja) 2009-01-29
JP2009502208A5 JP2009502208A5 (enExample) 2010-07-15

Family

ID=37727967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525274A Pending JP2009502208A (ja) 2005-08-05 2006-08-07 エネルギーホメオスタシスに関係する新規ペプチド

Country Status (10)

Country Link
US (4) US20090253619A1 (enExample)
EP (1) EP1928487A4 (enExample)
JP (1) JP2009502208A (enExample)
KR (1) KR101004662B1 (enExample)
CN (1) CN101505786A (enExample)
AU (2) AU2006278406B2 (enExample)
CA (1) CA2618047C (enExample)
IL (2) IL189065A (enExample)
RU (2) RU2409590C2 (enExample)
WO (1) WO2007019426A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US11246912B2 (en) * 2017-08-30 2022-02-15 Hadasit Medical Research Services & Development Ltd. Methods for treating and diagnosing metastatic liver cancer
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
WO2024263938A2 (en) * 2023-06-23 2024-12-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Using enho gene therapy to treat cardiometabolic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078345C1 (ru) * 1992-04-03 1997-04-27 Аникеева Светлана Петровна Способ получения сывороточного белкового препарата, влияющего на активность окислительно-энергетического обмена
US20030096951A1 (en) * 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
AU2006278406A1 (en) 2007-02-15
CA2618047C (en) 2015-04-14
US20160102126A1 (en) 2016-04-14
IL189065A (en) 2012-10-31
WO2007019426A2 (en) 2007-02-15
RU2010119559A (ru) 2011-11-20
AU2010202600A1 (en) 2010-07-15
US20130231280A1 (en) 2013-09-05
EP1928487A4 (en) 2009-11-04
US8518892B2 (en) 2013-08-27
CA2618047A1 (en) 2007-02-15
AU2006278406B2 (en) 2010-03-25
WO2007019426A3 (en) 2009-04-23
CN101505786A (zh) 2009-08-12
IL189065A0 (en) 2008-08-07
IL207764A0 (en) 2010-12-30
KR20080042866A (ko) 2008-05-15
RU2008108509A (ru) 2009-09-10
AU2010202600B2 (en) 2012-07-19
US20090253619A1 (en) 2009-10-08
KR101004662B1 (ko) 2011-01-03
US20100299769A1 (en) 2010-11-25
RU2409590C2 (ru) 2011-01-20
EP1928487A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
JP3786909B2 (ja) ポリペプチド及び同じものをコードしている核酸
US20160102126A1 (en) Novel Peptides Involved in Energy Homeostasis
EP1180114B1 (en) Use of resisitin specific antibodies in the treatment of diabetes
DK2440233T3 (en) SorCS1-like means for use in the treatment of insulin resistance and diseases associated therewith
CN103140234B (zh) 用于治疗肾病综合征和有关病症的方法
CA2422068A1 (en) Method for treatment of insulin resistance in obesity and diabetes
US9475850B2 (en) Methods for treatment of nephrotic syndrome and related conditions
CA3152699C (en) Methods for treatment of nephrotic syndrome and related conditions
HK1135608A (en) A novel peptide involved in energy homeostasis
JPWO2005097171A1 (ja) 抗肥満薬
MXPA00005354A (en) Polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111005